Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID19-VAX-AZG / COVID19-VAX-DBI-AZG / COVID19-VAX-XBB-AZG immune response study in healthy volunteers
2021-001304-15Phase 4Completed
- Sponsor
- AZ Groeninge
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of raxtozinameran in coronavirus disease 2019 (COVID-19), sponsored by AZ Groeninge. Primary endpoint: Induction of virus-specific antibodies. Started Mar 2021; status: completed.
02
Drugs
raxtozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-001304-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001304-15.